Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors

Cancer Gene Therapy

Volumn 8, Issue 6, 2001, Pages 450-458

  Huang, Z ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

Cancer gene therapy; Cyclophosphamide; P450; Prodrug activation

Indexed keywords

1 AMINOBENZOTRIAZOLE; 4 ETHYL 1,4 DIHYDRO 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; CHLORAMPHENICOL DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; FLAVOPROTEIN; FLUCYTOSINE; GANCICLOVIR; IFOSFAMIDE; METYRAPONE; PROADIFEN; PRODRUG; THIAMAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER; CONTROLLED STUDY; DRUG ACTIVATION; DRUG HALF LIFE; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE THERAPY; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BODY WEIGHT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE THERAPY; LIVER; MALE; METYRAPONE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; TIME FACTORS;

ANIMALIA; MAMMALIA;

EID: 0034885956     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700325     Document Type: Article

References (43)

1. Gene therapy for cancer using tumour-specific prodrug activation
2. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer
3. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm
4. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
5. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
6. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
7. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
8. Cytochrome P450-based cancer gene therapy: Recent advances and future prospects
9. An overview of cyclophosphamide and ifosfamide pharmacology
10. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes
11. Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles
12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
13. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy
14. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
15. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
16. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450
17. The macrophage - A novel system to deliver gene therapy to pathological hypoxia
18. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene
19. Interaction of anticancer drugs with hepatic monooxygenase enzymes
20. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy
21. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol
22. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma
23. The role of the bystander effect in suicide gene therapy
24. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model
25. The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers
26. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector
27. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450
28. m catalysts of cyclophosphamide and ifosfamide activation
29. HPLC fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations
30. In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: Impact on pharmacokinetics and antitumor activity
31. Determination of subcutaneous tumor size in athymic (nude) mice
32. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours
33. Oxidative metabolism of cyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation
34. Isozyme selectivity of the inhibition of rat liver cytochromes P450 by chloramphenicol in vivo
35. Cytochrome P450 isozyme 1 from phenobarbital-induced rat liver: Purification, characterization, and interactions with metyrapone and cytochrome b5
36. Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: A case for distinct proteolytic mechanisms?
37. 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats
38. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism
39. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
40. Selective suppression of rat hepatic cytochrome P450 2C11 by chloramphenicol
41. On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P450 by chloramphenicol
42. A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats